Biotechnology Company Announces Successful Preclinical Study Results For Psoriasis Treatment
Promising In-Vivo Results for Scinai Immunotherapeutics' Psoriatic Human Skin Model.
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biotechnology company known for its focus on developing inflammation and immunology (I&I) biological products, has announced successful in-vivo preclinical study results. The results pertain to its innovative anti IL-17A/F VHH antibody fragment, known as 'NanoAb', which functions as a local intralesional biological treatment specifically designed for patients suffering from mild to moderate plaque psoriasis. $Scinai Immunotherapeutics(SCNI.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
